Irinotecan - Starpharma

Drug Profile

Irinotecan - Starpharma

Alternative Names: DEP® irinotecan

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Starpharma
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer

Most Recent Events

  • 01 Oct 2017 Starpharma plans clinical development for Colorectal cancer (Starpharma Shareholder Update, October 2017)
  • 19 Jul 2017 Preclinical trials in Colorectal cancer in Australia (unspecified route)
  • 19 Jul 2017 Pharmacodynamics data from a preclinical studies in Colorectal cancer released by Starpharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top